Medical Beauty Injections Market Size, Share, Growth, and Industry Analysis, By Type (Filler Materials, Supplementary Materials, Support Materials, Shrinking Materials), By Application (Medical Beauty Institution, Hospital, Others), Regional Insights, and Forecast to 2035

Medical Beauty Injections Market Overview

Global Medical Beauty Injections market size is anticipated to be worth USD 4530.16 million in 2026, projected to reach USD 8178.95 million by 2035 at a 6.8% CAGR.

The Medical Beauty Injections Market is expanding as minimally invasive aesthetic procedures become more widely accepted across dermatology clinics, hospitals, medical beauty institutions, and specialized cosmetic centers. Injectable procedures increasingly address facial contouring, wrinkle reduction, volume restoration, skin rejuvenation, and structural enhancement without conventional surgery. Hyaluronic acid fillers, collagen-stimulating injectables, neuromodulators, and other supplementary materials are becoming central to personalized aesthetic treatment programs. Industry demand is also supported by improving injection techniques, practitioner training, combination treatments, and growing preference for natural-looking outcomes. Approximately 70% of aesthetic injectable demand is associated with facial enhancement and rejuvenation procedures, strengthening the Medical Beauty Injections Market Outlook.

The United States represents one of the most developed markets for medical beauty injections because of its extensive dermatology infrastructure, established medical-spa network, and high awareness of nonsurgical cosmetic treatments. Approximately 64% of aesthetic patients in major urban treatment centers show preference for procedures involving limited recovery time. Facial rejuvenation remains particularly important, while combination approaches involving fillers, collagen stimulators, and neuromodulators are becoming more common. More than 55% of injectable consultations are associated with facial lines, contour modification, volume restoration, or skin-quality improvement. Strong practitioner education and broad access to trained injectors continue supporting Medical Beauty Injections Market Growth across the country.

Key Findings

• Key Market Driver: Approximately 68% of prospective aesthetic consumers increasingly prefer minimally invasive cosmetic procedures because they provide comparatively short treatment sessions, limited downtime, and customizable facial enhancement.
• Major Market Restraint: Nearly 31% of potential consumers identify treatment expense, repeated maintenance requirements, safety concerns, or uncertainty regarding practitioner expertise as barriers to undergoing injectable aesthetic procedures.
• Emerging Trends: Around 57% of treatment interest is shifting toward subtle facial enhancement, skin-quality improvement, regenerative aesthetics, and individualized injection protocols instead of visibly dramatic cosmetic alteration.
• Regional Leadership: North America accounts for approximately 36% of Medical Beauty Injections Market activity, supported by established aesthetic clinics, experienced practitioners, strong product availability, and repeat-treatment demand.
• Competitive Landscape: Leading multinational and specialist injectable manufacturers collectively influence approximately 62% of branded treatment activity through extensive filler portfolios, practitioner education, clinical research, and distribution networks.
• Market Segmentation: Filler materials represent approximately 46% of type-based demand because facial volumization, contour correction, wrinkle management, lip enhancement, and structural facial treatments remain widely requested procedures.
• Recent Development: Approximately 41% of product-development emphasis is associated with longer-lasting formulations, improved rheological properties, regenerative treatment concepts, natural-looking outcomes, and broader facial or body indications.

Medical Beauty Injections Market Latest Trends

Medical Beauty Injections Market Trends increasingly center on individualized outcomes rather than standardized correction. Approximately 59% of treatment planning in established aesthetic practices emphasizes facial balance, movement preservation, skin quality, and natural appearance. Hyaluronic acid formulations remain important because practitioners can select products according to lifting capacity, tissue integration, projection, flexibility, and injection depth. Regenerative approaches are simultaneously gaining attention as consumers seek progressive improvements in firmness and texture. Approximately 43% of advanced treatment protocols now incorporate multiple aesthetic objectives rather than addressing a single wrinkle or isolated facial area.

Combination therapy is another important direction within Medical Beauty Injections Industry Analysis. Approximately 52% of experienced aesthetic providers report increased patient interest in treatment plans combining volumization, collagen stimulation, neuromodulation, and skin-quality improvement. Younger consumers are increasingly requesting preventative or low-volume treatments, while mature patient groups generally require restoration across multiple facial zones. Digital facial assessment, standardized photography, anatomical mapping, and structured consultation processes are also improving treatment personalization. Around 48% of premium clinics increasingly emphasize staged procedures, allowing injectors to evaluate tissue response before adding further correction and supporting controlled, natural-looking outcomes.

Medical Beauty Injections Market Dynamics

DRIVER

"Growing preference for minimally invasive aesthetic enhancement"

The primary Medical Beauty Injections Market Growth driver is consumer preference for aesthetic treatments that can be completed without major surgery or lengthy recovery. Approximately 68% of aesthetic consumers favor minimally invasive approaches when suitable alternatives to surgical correction are available. Injectable treatments can address facial volume loss, wrinkles, contour definition, lip enhancement, chin projection, and skin-quality concerns through relatively short clinical appointments. Social acceptance has also broadened as aesthetic treatments become increasingly associated with maintenance and personalized appearance management rather than major cosmetic transformation. Approximately 54% of repeat patients seek conservative adjustments instead of extensive correction. Growing numbers of dermatologists, plastic surgeons, aesthetic physicians, and trained injectors further improve accessibility.

RESTRAINTS

"Safety concerns and dependence on qualified practitioners"

Medical Beauty Injections Market expansion remains constrained by concerns surrounding improper injection, counterfeit products, adverse reactions, unrealistic expectations, and treatments performed by insufficiently trained providers. Approximately 31% of hesitant consumers identify safety and practitioner qualification among their principal concerns before treatment. Injectable procedures require detailed anatomical knowledge because incorrect placement can result in asymmetry, vascular complications, swelling, nodules, or unsatisfactory cosmetic outcomes. Treatment maintenance also affects consumer decisions because many injectable results are temporary and require follow-up procedures. Around 37% of price-sensitive consumers consider repeated treatment frequency before committing to long-term aesthetic programs. Manufacturers and medical institutions are consequently increasing education, traceability, standardized injection protocols, and post-treatment guidance. 

OPPORTUNITY

"Expansion of regenerative and personalized aesthetic treatments"

Medical Beauty Injections Market Opportunities are expanding as the industry moves beyond conventional wrinkle filling toward regenerative aesthetics, structural correction, facial harmonization, and skin-quality improvement. Approximately 57% of emerging consumer interest favors natural-looking outcomes that preserve recognizable facial characteristics. This creates opportunities for advanced hyaluronic acid products, collagen stimulators, biocompatible materials, and treatment combinations designed around individual anatomy. Manufacturers can differentiate through products engineered for specific facial layers, tissue characteristics, flexibility requirements, or projection needs. Around 45% of premium aesthetic practices increasingly promote comprehensive treatment planning instead of single-area correction. Emerging markets also offer substantial opportunity as practitioner training, disposable income, social acceptance, and access to branded products improve. Companies investing in clinical evidence, injector education, indication expansion, and region-specific product strategies can strengthen their Medical Beauty Injections Market Share.

CHALLENGE

"Balancing treatment longevity with natural outcomes and safety"

A central Medical Beauty Injections Market challenge involves providing durable aesthetic improvement while preserving facial movement, tissue compatibility, reversibility where appropriate, and predictable safety. Approximately 46% of experienced consumers prioritize natural appearance over maximum volumization, requiring manufacturers and injectors to reconsider older treatment philosophies focused heavily on correction volume. Different facial areas require different material characteristics, making product selection increasingly technical. Approximately 42% of advanced treatment planning considers multiple variables including tissue thickness, injection plane, facial movement, age-related structural change, and previous procedures. Competitive pressure also requires manufacturers to generate clinical evidence supporting performance claims while meeting differing regulatory requirements across countries. Clinics must simultaneously manage patient expectations shaped by social media and digitally altered imagery. These factors make practitioner education, consultation quality, patient selection, and evidence-based treatment planning essential to sustainable Medical Beauty Injections Market Growth.

Medical Beauty Injections Market Segmentation

The Medical Beauty Injections Market Analysis segments demand by injectable material and treatment environment. By type, filler materials account for 46%, supplementary materials represent 23%, support materials contribute 18%, and shrinking materials account for 13%, totaling 100%. By application, medical beauty institutions hold 58%, hospitals account for 29%, and other treatment settings represent 13%, also totaling 100%. Differences between segments reflect treatment purpose, provider specialization, injection technique, patient profile, product availability, and expected aesthetic outcome. Specialized medical beauty institutions lead application demand because injectable treatments form a core component of their service portfolios and generate substantial repeat-patient activity.

BY TYPE

Filler Materials: Filler materials account for 46% of Medical Beauty Injections Market type demand and represent the largest segment. These materials are widely employed for facial volumization, contour definition, wrinkle correction, lip enhancement, chin shaping, cheek augmentation, and restoration of age-related volume loss. Hyaluronic acid-based formulations remain particularly important because different rheological characteristics allow practitioners to select products for superficial lines, dynamic facial areas, deep structural support, or projection. Clinical practice increasingly favors product-specific placement rather than using one formulation throughout the face. Patient expectations are also changing toward balanced and anatomically appropriate outcomes. Filler procedures can be incorporated into staged treatment plans and combined with other injectable categories. The segment benefits from broad physician familiarity, extensive practitioner education, continued formulation innovation, and consumer recognition, making filler materials fundamental to Medical Beauty Injections Market Research Report assessments.

Supplementary Materials: Supplementary materials represent 23% of Medical Beauty Injections Market demand and support procedures intended to improve treatment quality, tissue condition, hydration, recovery, or overall aesthetic outcomes. This segment includes injectable and procedure-supporting materials that complement primary correction rather than functioning solely as traditional volumizing products. Approximately 44% of clinics offering advanced aesthetic programs increasingly integrate supplementary approaches into multi-stage facial rejuvenation plans. Their role is expanding as treatment philosophy moves toward comprehensive management of skin quality, facial structure, and age-related changes. Supplementary materials can help practitioners customize protocols according to patient age, tissue characteristics, treatment history, and desired outcome. Demand is strongest in premium medical beauty institutions where patients frequently undergo multiple complementary procedures. 

Support Materials: Support materials hold approximately 18% of type-based Medical Beauty Injections Market activity. Their use is associated with aesthetic treatment approaches emphasizing structural support, tissue remodeling, progressive improvement, or complementary correction alongside conventional fillers. Approximately 39% of advanced aesthetic treatment plans evaluate structural characteristics before addressing superficial lines, demonstrating increasing recognition that facial aging involves multiple anatomical layers. Support materials can be selected to improve treatment architecture and provide more comprehensive facial harmonization. Demand is influenced by practitioner expertise because advanced injection strategies require careful understanding of facial anatomy and appropriate placement. Specialized clinics are important users because they can offer detailed assessment and follow-up. Medical Beauty Injections Industry Analysis indicates that this segment benefits from growing interest in regenerative aesthetics and treatment approaches designed to improve facial quality progressively rather than producing excessive immediate correction.

Shrinking Materials: Shrinking materials account for approximately 13% of Medical Beauty Injections Market type demand and are associated with procedures focused on contour refinement, targeted aesthetic correction, and treatments where reduction or tightening effects complement volumization strategies. Approximately 34% of consumers seeking facial contour procedures indicate interest in sharper definition rather than additional volume, creating a distinct role for this category. Treatments are particularly relevant where practitioners need to balance facial proportions or manage localized aesthetic concerns. The segment remains more specialized than filler materials because patient selection, treatment planning, and anatomical evaluation significantly influence suitability. Medical beauty institutions offering comprehensive contour-management programs represent important treatment environments. Continued practitioner education and development of evidence-supported protocols can increase adoption. The category also benefits from growing consumer awareness that aesthetic injection strategies may involve reshaping and balancing facial proportions rather than simply adding volume.

BY APPLICATION

Medical Beauty Institution: Medical beauty institutions account for 58% of application-based Medical Beauty Injections Market activity, making them the dominant treatment channel. These facilities specialize in aesthetic procedures and generally maintain dedicated injectable portfolios, trained practitioners, consultation systems, standardized photography, treatment rooms, and follow-up services. Approximately 63% of patients using specialized institutions consider practitioner experience an important selection factor. Medical beauty institutions also generate repeat demand because many filler, neuromodulator, and regenerative procedures involve staged treatment or periodic maintenance. Their ability to offer multiple brands enables practitioners to select formulations according to facial area, desired correction, tissue depth, and patient preference. Combination treatment is particularly important within this segment, as clinics increasingly address several aesthetic concerns during coordinated treatment programs. Strong patient education, digital marketing, consultation infrastructure, and practitioner training continue reinforcing this segment's leadership.

Hospital: Hospitals represent approximately 29% of Medical Beauty Injections Market application demand. Dermatology departments, plastic surgery units, reconstructive services, and specialized aesthetic centers within hospitals provide injectable procedures supported by broader medical infrastructure. Approximately 47% of patients with complex aesthetic requirements place greater importance on medically supervised environments, especially when treatments involve previous surgery, reconstructive needs, underlying dermatological concerns, or multiple procedures. Hospital-based treatment can provide access to specialists with extensive anatomical and clinical experience. These environments also support complication management and multidisciplinary assessment when necessary. Although hospitals generally have lower procedure volumes than dedicated medical beauty chains, they retain significant importance in medically complex cases and premium physician-led services. Increasing establishment of hospital-affiliated cosmetic dermatology centers is widening access to evidence-based aesthetic injections and strengthening this application segment.

Others: Other applications account for 13% of Medical Beauty Injections Market demand and include physician offices, specialist dermatology practices, plastic surgery clinics, selected medical spas operating under appropriate medical supervision, and other authorized aesthetic treatment facilities. Approximately 36% of consumers value smaller treatment environments for personalized consultation, continuity with a preferred practitioner, and flexible appointment scheduling. Independent clinics can differentiate through specialized injection techniques, focused product portfolios, facial assessment expertise, and long-term patient relationships. This category is fragmented because regulations governing injectable administration differ substantially between countries and jurisdictions. Practitioner qualification and product authenticity therefore remain central considerations. Independent facilities increasingly adopt digital consultation tools, standardized before-and-after photography, patient management systems, and structured follow-up protocols. 

Medical Beauty Injections Market Regional Outlook

The Medical Beauty Injections Market demonstrates geographically diverse adoption, influenced by aesthetic awareness, practitioner availability, regulatory frameworks, disposable income, medical tourism, and access to established injectable brands. North America accounts for 36% of global activity, followed by Europe with 27%, Asia-Pacific with 25%, Middle East and Africa with 7%, and Rest of World with 5%, collectively representing 100%. Mature regions benefit from established dermatology and aesthetic medicine infrastructure, while emerging markets are experiencing increasing procedure penetration through expanding clinic networks, practitioner education, urbanization, and consumer acceptance of minimally invasive cosmetic treatments.

NORTH AMERICA

North America accounts for approximately 36% of Medical Beauty Injections Market activity, supported by extensive adoption of minimally invasive cosmetic procedures across the United States and Canada. Consumers increasingly seek facial rejuvenation, contour enhancement, volume restoration, wrinkle management, and skin-quality treatments delivered through specialized aesthetic clinics and physician-led practices.

The region benefits from established dermatology and plastic surgery networks, broad availability of injectable products, and strong practitioner education. Repeat procedures represent an important source of treatment activity because patients increasingly adopt maintenance-oriented aesthetic programs. Advanced consultation, facial mapping, combination therapy, and personalized injection protocols further strengthen regional demand.

EUROPE

Europe represents approximately 27% of Medical Beauty Injections Market activity. Demand is supported by established aesthetic medicine communities across major European countries and increasing consumer preference for subtle facial rejuvenation. Patients commonly seek procedures emphasizing facial balance, wrinkle reduction, volume restoration, and natural-looking improvements rather than extensive cosmetic alteration.

European practitioners increasingly emphasize conservative injection volumes, anatomical assessment, product traceability, and individualized treatment planning. Medical beauty clinics, dermatology practices, and plastic surgery centers remain important distribution channels. Growing adoption of collagen-stimulating approaches and skin-quality treatments is also broadening injectable applications beyond conventional wrinkle correction and facial volumization.

ASIA-PACIFIC

Asia-Pacific holds approximately 25% of Medical Beauty Injections Market activity and continues expanding through increasing aesthetic awareness, urbanization, medical tourism, and growth in specialist cosmetic clinics. Demand is particularly visible across developed and rapidly urbanizing markets where younger consumers increasingly incorporate minimally invasive treatments into routine appearance-management programs.

Regional preferences frequently emphasize facial contouring, skin quality, balanced proportions, and subtle enhancement. Domestic manufacturers are also expanding their participation alongside international injectable brands. Practitioner education, social-media awareness, expanding middle-income populations, and greater availability of specialized aesthetic institutions are supporting wider adoption across major metropolitan and secondary urban markets.

MIDDLE EAST AND AFRICA

Middle East and Africa accounts for approximately 7% of Medical Beauty Injections Market activity. Demand is concentrated primarily in affluent urban centers where specialized dermatology clinics, cosmetic surgery practices, and premium medical beauty institutions provide injectable treatments. Facial contouring, rejuvenation, wrinkle correction, and individualized enhancement represent important procedure categories.

Medical tourism and development of premium healthcare infrastructure are contributing to regional market visibility. Consumer awareness remains uneven across the broader region, creating considerable differences in procedure penetration. Expansion of trained practitioner networks, improved access to authentic products, and growing availability of specialized clinics could support broader injectable adoption over time.

REST OF WORLD

Rest of World represents approximately 5% of Medical Beauty Injections Market activity, reflecting developing aesthetic treatment ecosystems across several emerging countries. Injectable adoption is primarily concentrated in major cities where consumers have access to dermatologists, plastic surgeons, aesthetic physicians, and specialist medical beauty clinics offering professionally administered cosmetic procedures.

Increasing awareness of nonsurgical facial enhancement is supporting gradual market development. However, differences in product availability, practitioner density, regulation, affordability, and consumer purchasing power continue influencing adoption. Growing medical tourism and improved professional training provide opportunities for branded injectable manufacturers and specialist aesthetic providers seeking expansion into developing markets.

List of top Medical Beauty Injections Market Companies

• AbbVie
• LG Chem
• Haohai Biological Technology
• Bloomage Biotechnology
• Galderma
• Aimei Ke
• Changchun Botai Pharmaceutical Biotechnology
• Sunmax Biotechnology
• Sinclair Pharma
• Hafod BioScience B.V.

Top Two Companies with Highest Market Share

• AbbVie: The company maintains substantial injectable-aesthetics participation through an established product portfolio, extensive practitioner relationships, international commercialization infrastructure, and broad presence across professional aesthetic treatment channels.
• Galderma: The company maintains a significant competitive position through its diversified injectable aesthetics portfolio, professional education programs, clinical development activities, and established presence across specialist dermatology and aesthetic medicine practices.

Investment Analysis and Opportunities

Investment activity in the Medical Beauty Injections Market increasingly focuses on product innovation, manufacturing capacity, clinical evidence, practitioner training, and expansion of specialized aesthetic treatment networks. Approximately 57% of emerging consumer interest centers on natural-looking enhancement, creating opportunities for manufacturers developing products with specialized rheological characteristics, improved tissue integration, and targeted applications. Medical beauty institutions also represent attractive investment targets because they account for 58% of application-based demand and frequently generate recurring patient activity through maintenance treatments. Businesses capable of integrating consultation, treatment, follow-up, and personalized aesthetic planning can strengthen patient retention while supporting multiple injectable categories. Additional opportunities exist in professional education platforms, authenticated product distribution, digital facial assessment, patient-management systems, and standardized clinical photography.

Asia-Pacific and selected emerging markets provide further opportunities as specialized clinic networks expand and minimally invasive aesthetics become more familiar to consumers. Asia-Pacific represents 25% of market activity, creating opportunities for localized product portfolios, practitioner education, and regional manufacturing partnerships. Investment strategies increasingly emphasize treatment personalization rather than simple product volume. Manufacturers can differentiate by supporting practitioners with anatomical education, injection protocols, clinical studies, and post-treatment guidance. Specialized formulations for different tissue depths and facial areas also create opportunities for portfolio expansion. Investors are additionally evaluating regenerative aesthetics, collagen stimulation, combination treatments, and skin-quality injectables as adjacent growth categories. Companies combining credible clinical evidence with effective professional distribution are positioned to address increasingly sophisticated purchasing requirements among clinics and aesthetic practitioners.

New Products Development

New product development within the Medical Beauty Injections Market increasingly emphasizes improved tissue integration, application-specific characteristics, natural facial movement, durability, and predictable treatment outcomes. Approximately 46% of experienced aesthetic consumers prioritize natural-looking results, encouraging manufacturers to develop formulations that provide correction without excessive projection or stiffness. Product portfolios are becoming increasingly specialized, with different injectable materials designed for lips, cheeks, jawlines, chin structures, superficial lines, dynamic facial areas, and skin-quality improvement. Manufacturers are also evaluating regenerative mechanisms and collagen-stimulating technologies as aesthetic medicine expands beyond traditional volumization. Approximately 41% of development emphasis across advanced aesthetic portfolios is associated with longer-lasting results, improved material characteristics, or broader treatment applications. These innovations enable practitioners to create increasingly individualized treatment strategies.

Development programs are also placing greater importance on injection handling, product consistency, patient comfort, packaging, traceability, and practitioner usability. Around 52% of advanced aesthetic providers demonstrate interest in combination treatment approaches, encouraging manufacturers to design complementary portfolios rather than isolated products. Clinical research remains central because providers increasingly expect evidence regarding treatment duration, tissue behavior, adverse-event profiles, and appropriate injection techniques. Product innovation is simultaneously expanding into regenerative and skin-quality categories, where patients seek gradual improvements rather than immediate structural correction. Manufacturers capable of combining specialized formulations with professional education can improve adoption among trained injectors. Digital training, anatomical simulation, standardized protocols, and real-world clinical education are therefore becoming increasingly connected to successful new-product commercialization.

Five Recent Developments 

• 2025 – Galderma expanded the Relfydess rollout: Galderma continued expanding the availability of its ready-to-use liquid neuromodulator across additional markets following earlier regulatory clearances. The development strengthened its injectable aesthetics portfolio and increased practitioner access to a product designed for glabellar lines and lateral canthal lines.
• 2025 – AbbVie advanced aesthetics portfolio development: AbbVie's Allergan Aesthetics business continued developing and commercializing products across its established injectable aesthetics portfolio, with emphasis on facial assessment, practitioner education, and treatment personalization. Its aesthetics strategy continued to combine neuromodulators and dermal fillers across professional treatment practices.
• 2024 – Galderma received European authorization for Relfydess: Galderma announced decentralized procedure completion resulting in positive decisions for Relfydess in Europe. The ready-to-use liquid neuromodulator was developed for temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines, broadening Galderma's injectable aesthetics offering.
• 2024 – Allergan Aesthetics expanded JUVÉDERM clinical positioning: Allergan Aesthetics continued supporting its JUVÉDERM portfolio through professional education and treatment-planning initiatives addressing facial structure, contouring, and volume restoration. Portfolio-based treatment strategies reflected increasing demand for individualized correction across multiple facial areas.
• 2023 – Galderma received U.S. FDA approval for Restylane Eyelight: Galderma announced U.S. approval of Restylane Eyelight for improvement of infraorbital hollowing in adults older than 21. The approval broadened the Restylane portfolio and provided practitioners with an additional hyaluronic-acid injectable option targeting the under-eye area.

Report Coverage

The Medical Beauty Injections Market Report provides comprehensive analysis of product categories, applications, competitive positioning, regional demand, investment priorities, product development, and major industry dynamics. Type analysis covers filler materials with 46% share, supplementary materials with 23%, support materials with 18%, and shrinking materials with 13%. Application analysis evaluates medical beauty institutions at 58%, hospitals at 29%, and other treatment settings at 13%. The Medical Beauty Injections Market Research Report also assesses consumer preference for minimally invasive treatments, personalized facial enhancement, natural-looking results, regenerative approaches, combination procedures, practitioner education, safety considerations, and development of specialized injectable formulations.

Regional coverage evaluates North America with 36% share, Europe with 27%, Asia-Pacific with 25%, Middle East and Africa with 7%, and Rest of World with 5%. Competitive coverage includes AbbVie, LG Chem, Haohai Biological Technology, Bloomage Biotechnology, Galderma, Aimei Ke, Changchun Botai Pharmaceutical Biotechnology, Sunmax Biotechnology, Sinclair Pharma, and Hafod BioScience B.V. The Medical Beauty Injections Industry Report further examines opportunities associated with aesthetic clinic expansion, professional injector training, digital treatment planning, product traceability, collagen stimulation, skin-quality improvement, and advanced facial harmonization. This coverage supports B2B stakeholders evaluating Medical Beauty Injections Market Trends, Medical Beauty Injections Market Share, competitive strategies, distribution opportunities, and evolving treatment requirements.